Medtech
Etcembly Announces Breakthrough in Optimising TCR Assets
Etcembly, a tech-bio company transforming the precision, scale, and speed of development of T cell receptor (TCR) immunotherapies,announced the successful…
Etcembly, a tech-bio company transforming the precision, scale, and speed of development of T cell receptor (TCR) immunotherapies,announced the successful prediction and optimisation of multiple TCR assets for targeting leukamias and solid tumours. The company’s pioneering machine learning platform EMLy (Etcembly Machine Learning) enables AI based engineering of novel TCRs from the complete theoretical TCR repertoire. The unification of machine learning based optimisation with empirical validation has facilitated the rapid decoding of disease relevant T Cell repertoires giving rise to TCRs primed for the clinic in half the development timeline.
The company has also closed a financing round, bringing on board new international investor, Singapore VC iGlobe Partners. Financial details were not disclosed.
Etcembly’s CTO and co-founder Jacob Hurst added, “EMLy can adeptly interrogate our massive database of TCR repertoires. Not only can we expertly find new TCRs, but we can also re-engineer existing TCR based assets to improve affinity and potency. Importantly, our approach is haplotype independent, which means we can help companies with the Holy Grail of developing immunotherapies that have global therapeutic value. We see EMLy as the oracle of immunotherapy for our pharmaceutical partners.”
Recommended AI News: Fastly Acquires Fanout to Unlock Real-Time App Development at the Edge
Soo Boon Koh, Founder and Managing Partner at iGlobe Partners said, “At iGlobe Partners we unearth, invest, and grow start-ups into global leaders. We have a strong track record of scaling game-changing innovations and see tremendous potential to do that with EMLy. We have been impressed by the speed at which the platform has been able to predict and optimise TCR assets.”
Recommended AI News: OmniML Secures $10 Million to Accelerate AI Computing on Edge Devices
Etcembly’s Board Director, and founder of Immunocore and Adaptimmune, Bent Jakobsen, added, “Immunotherapy has advanced massively as a therapeutic approach since I founded Immunocore and Adaptimmune. It now brings great benefit to patients and society and holds immense promise for further developments. TCRs may prove to be the most important component for realising this potential, but deciphering their specificities is amongst the most complex challenges in biology. Etcembly’s platform has now broken the last barrier by enabling sourcing from the full repertoire of possible TCRs. Put simply, EMLy enables drug hunters to see further, move faster, and be more successful.”
Recommended AI News: CommScope Propels Data Centers into the Future
[To share your insights with us, please write to sghosh@martechseries.com]
The post Etcembly Announces Breakthrough in Optimising TCR Assets appeared first on AiThority.
ETF Talk: AI is ‘Big Generator’
Second nature comes alive Even if you close your eyes We exist through this strange device — Yes, “Big Generator” Artificial intelligence (AI) has…
Apple gets an appeals court win for its Apple Watch
Apple has at least a couple more weeks before it has to worry about another sales ban.
Federal court blocks ban on Apple Watches after Apple appeal
A federal appeals court has temporarily blocked a sweeping import ban on Apple’s latest smartwatches while the patent dispute winds its way through…
